8-K: Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results

Pulmonx Corporation announced record fourth quarter and full year 2024 financial results, driven by increased revenue and strategic initiatives.

Summary

• Pulmonx reported a 22% increase in worldwide revenue for the full year 2024, reaching $83.8 million.
• The company achieved record worldwide revenue of $23.8 million for the fourth quarter of 2024, a 23% increase year-over-year.
• U.S. revenue reached a record $15.9 million in Q4 2024 and $56.5 million for the full year, representing 16% and 23% year-over-year growth, respectively.
• The gross margin was 74% in both the fourth quarter and the full year of 2024.
• The net loss for the full year 2024 was $56.4 million, or $1.44 per share, compared to a net loss of $60.8 million, or $1.60 per share, in 2023.
• Adjusted EBITDA loss for the full year 2024 was $31.3 million, an improvement from the $39.0 million loss in 2023.
• Pulmonx expects full year 2025 revenue to be in the range of $96 million to $98 million, representing growth of 15% to 17%.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to strong revenue growth and strategic initiatives, but tempered by continued net losses and increasing operating expenses. The company's guidance for 2025 suggests continued growth, but the risks associated with forward-looking statements should be considered.

Positives

• Significant revenue growth in both Q4 and full year 2024, driven by increased adoption of Zephyr Valve procedures.
• Consistent gross margin of 74% indicates efficient cost management.
• Expansion of U.S. treatment centers with the addition of 11 new Zephyr Valve centers in Q4 2024.
• Partnership with the American Lung Association to enhance COPD patient and provider education.
• Launch of the LungTraX software platform in pilot sites, potentially optimizing patient workflows.
• Improved Adjusted EBITDA loss for both Q4 and full year 2024 compared to the previous year.

Negatives

• The company continues to experience a net loss, although it has decreased compared to the previous year.
• Operating expenses increased, primarily due to investments in commercial activities and clinical development costs.
• The company is still loss making with an Adjusted EBITDA loss of $31.3 million for the full year.

Risks

• The company's future performance is subject to risks and uncertainties detailed in its SEC filings.
• The forward-looking statements are based on current assumptions and expectations, and actual results may differ materially.
• The company's ability to achieve its revenue guidance for 2025 depends on various factors, including market conditions and adoption rates.

Future Outlook

Pulmonx expects full year 2025 revenue to be in the range of $96 million to $98 million, representing growth of 15% to 17%. The company expects a gross margin of approximately 74% and total operating expenses between $133 million and $135 million.

Management Comments

• Steve Williamson, President & Chief Executive Officer, stated that the record results underscore the success of the company's focused strategy and execution.
• Management is confident in their ability to drive long-term, sustainable growth in 2025 and beyond.

Industry Context

Pulmonx operates in the minimally invasive treatments market for lung diseases, specifically targeting COPD and emphysema. The company's growth is driven by the increasing adoption of its Zephyr Valve and related technologies. The partnership with the American Lung Association indicates a focus on expanding market awareness and education.

Comparison to Industry Standards

• It's difficult to provide a direct comparison without knowing the specific growth rates and financial metrics of Pulmonx's direct competitors in the minimally invasive lung disease treatment market.
• Companies like Olympus and Boston Scientific also operate in the broader respiratory device market, but their specific focus and product portfolios differ from Pulmonx.
• A 74% gross margin is generally considered healthy for a medical device company, suggesting efficient manufacturing and pricing strategies.
• However, the continued net losses and reliance on adjusted EBITDA as a key performance indicator suggest that Pulmonx is still in a growth phase and investing heavily in commercialization and R&D.

Stakeholder Impact

• Shareholders will likely react positively to the revenue growth and improved EBITDA loss, but will also be mindful of the continued net losses.
• Employees may benefit from the company's growth and expansion, but may also face pressure to meet ambitious revenue targets.
• COPD patients and providers may benefit from the company's educational initiatives and the LungTraX software platform.
• Suppliers may see increased demand for Pulmonx's products and services.
• Creditors will likely monitor the company's cash flow and debt levels.

Next Steps

• Pulmonx will continue to focus on expanding its account base, optimizing patient workflows, and raising awareness among patients and referring physicians.
• The company will monitor the pilot launch of the LungTraX software platform and assess its impact on patient outcomes and workflow efficiency.
• Pulmonx will execute on its commercial strategy to achieve its revenue guidance for 2025.

Key Dates